Two different sides of ‘chemobrain’: determinants and nondeterminants of self‐perceived cognitive dysfunction in a prospective, randomized, multicenter study

Objective: Complaints of cognitive dysfunction are frequent among cancer patients. Many studies have identified neuropsychological compromise associated with cancer and cancer therapy; however, the neuropsychological compromise was not related to self‐reported cognitive dysfunction. In this prospective study, the authors examined if confounding factors masked an underlying association of self‐perceived cognitive function with actual cognitive performance. Determinants of self‐perceived cognitive dysfunction were investigated.

[1]  C. Hay,et al.  What do cancer patients mean when they complain of concentration and memory problems? , 1996, British Journal of Cancer.

[2]  M. J. van den Bent,et al.  Assessment of pre-treatment cognitive performance in adult bone marrow or haematopoietic stem cell transplantation patients: a comparative study. , 2005, European journal of cancer.

[3]  Uwe Koch,et al.  The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. , 2007, Patient education and counseling.

[4]  Pablo A. Mora,et al.  Elucidating the relationship between negative affectivity and symptoms: The role of illness-specific affective responses , 2007, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[5]  F. Petermann.  Hospital Anxiety and Depression Scale, Deutsche Version (HADS-D) , 2011 .

[6]  M. Muller,et al.  Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer , 2008, Acta oncologica.

[7]  Andrew J. Saykin,et al.  Cognitive function in breast cancer patients prior to adjuvant treatment , 2008, Breast Cancer Research and Treatment.

[8]  K. Lange,et al.  Cognitive dysfunction and subjective complaints of cancer patients. a cross-sectional study in a cancer rehabilitation centre. , 2004, European journal of cancer.

[9]  D. Watson,et al.  Development and validation of brief measures of positive and negative affect: the PANAS scales. , 1988, Journal of personality and social psychology.

[10]  E. Das,et al.  The influence of priming and pre‐existing knowledge of chemotherapy‐associated cognitive complaints on the reporting of such complaints in breast cancer patients , 2009, Psycho-oncology.

[11]  J. Kramer,et al.  Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide , 2008, Psycho-oncology.

[12]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[13]  I. Tannock,et al.  Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment , 2006, Psycho-oncology.

[14]  S. Rodenhuis,et al.  Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. , 1998, Journal of the National Cancer Institute.

[15]  M. Lux,et al.  Short‐term effects of treatment‐induced hormonal changes on cognitive function in breast cancer patients , 2008, Cancer.

[16]  P. Fasching,et al.  PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer: A preplanned interim analysis of eff , 2008 .

[17]  James W. Pennebaker,et al.  The psychology of physical symptoms , 1982 .

[18]  J. Henry,et al.  The positive and negative affect schedule (PANAS): construct validity, measurement properties and normative data in a large non-clinical sample. , 2004, The British journal of clinical psychology.

[19]  M. Muller,et al.  Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma , 1999, Cancer.

[20]  Susan M. Richey,et al.  What do perceived cognitive problems reflect? , 2008, The journal of supportive oncology.

[21]  Carl-Walter Kohlmann,et al.  Untersuchungen mit einer deutschen Version der "Positive and Negative Affect Schedule" (PANAS). , 1996 .

[22]  P. Costa,et al.  Neuroticism, somatic complaints, and disease: is the bark worse than the bite? , 1987, Journal of personality.

[23]  C. Gundy,et al.  Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: Cross-sectional findings from the neuropsychological TEAM-side study , 2009, Acta oncologica.

[24]  D. Ronis,et al.  Pre‐treatment factors related to cognitive functioning in women newly diagnosed with breast cancer , 2005, Psycho-oncology.

[25]  D. Watson,et al.  Health complaints, stress, and distress: exploring the central role of negative affectivity. , 1989, Psychological review.

[26]  P. Costa,et al.  Hypochondriasis, neuroticism, and aging. When are somatic complaints unfounded? , 1985, The American psychologist.

[27]  P. Ganz,et al.  Neurocognitive Performance in Breast Cancer Survivors Exposed to Adjuvant Chemotherapy and Tamoxifen , 2004, Journal of clinical and experimental neuropsychology.

[28]  D. Watson,et al.  Negative affectivity: the disposition to experience aversive emotional states. , 1984, Psychological bulletin.

[29]  Andrew J Saykin,et al.  Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  V. Shilling,et al.  Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. , 2007, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

[31]  M. Lux,et al.  Cognitive function during neoadjuvant chemotherapy for breast cancer , 2007, Cancer.